The present results demonstrated that high PD-L1 expression in tumor tissues and high PD-1 lymphocyte populations were related to long-term PEM responses, as well as to a high incidence of immune-related adverse events in patients treated with ICI therapy after long-term administration of PEM. This evidence concerns the gene CD274 and neoplasm.